Strasbourg and Paris, France, 26 August 2026 — Inoviem Scientific, a translational pharmacology company specialising in evaluating drug activity and mechanisms directly in human pathological tissue, and DeepLife, a Paris-based techbio company developing AI-powered digital twins of human cells, today announced a strategic collaboration focused on inflammatory bowel disease (IBD).
Through the collaboration, DeepLife leverages TwinCell, its proprietary virtual cells engine, an AI engine that integrates single-cell omics, causal modeling and cell-type-specific networks, to identify and prioritize novel target hypotheses in IBD along with their underlying cellular mechanisms. Inoviem then evaluates selected compounds or interventions linked to those targets in fresh human tissue to determine whether the predicted mechanisms produce measurable biological effects.
The initial programme will use fresh intestinal biopsies from patients in need of innovative drugs. By combining computational modelling with translational pharmacology, the companies aim to explore a more direct route from therapeutic hypothesis generation to experimental evidence in human disease tissue.
The collaboration establishes a lab-in-the-loop workflow that connects TwinCell-driven therapeutic prioritisation with direct human tissue evaluation, enabling pharmaceutical and biotechnology teams to iteratively refine therapeutic targets and make more informed go/no-go decisions earlier in the drug development process.
“TwinCell enables discovery teams to rapidly translate complex disease data into prioritized, mechanistically grounded therapeutic hypotheses,” said Jonathan Baptista, CEO & Founder of DeepLife. “By partnering with Inoviem, we can validate these hypotheses directly in patient-derived tissue, strengthening the evidence needed to advance the most promising therapeutic candidates.”
“The closer an experimental system is to the biology of the patient, the more meaningful the evidence becomes,” said Pierre Eftekhari, President & CSO of Inoviem Scientific. “By combining Inoviem’s expertise in translational ex vivo pharmacology using fresh human tissue with DeepLife’s computational approach, we aim to generate clearer and more actionable evidence for therapeutic decision-making.”
The initial IBD programme will allow the companies to assess the combined approach and determine whether it could be applied to additional disease areas over time.
About Inoviem Scientific
Inoviem Scientific, founded in 2011 and based in Strasbourg, is a translational pharmacology company that validates drug efficacy, mechanism and safety on primary human tissue. Its ex-vivo platforms generate human-relevant evidence for target validation, mechanism deconvolution and biomarker discovery across oncology, immunology and inflammation, fibrosis and other therapeutic areas.
About DeepLife
DeepLife is a Paris-based techbio company developing AI-powered digital twins of human cell types to support therapeutic decision-making. Its TwinCell platform combines harmonised single-cell omics data, causal modelling and cell-type-specific biological networks to help research teams investigate disease mechanisms, prioritise therapeutic targets and identify opportunities for drug discovery, indication expansion and repositioning.
Media contacts
Inoviem Scientific: contact@inoviem.com
DeepLife: hello@deeplife.co
